{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:24:44Z","timestamp":1789129484147,"version":"build-2803163510"},"reference-count":37,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Blinatumomab, a bispecific T-cell engager, mediates cytotoxicity through CD3+ T-cell activation and has shown efficacy in relapsed or refractory (R\/R) B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Although T-cell expansion correlates with favorable outcomes, routine immunophenotyping is impractical in clinical settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine whether early changes in absolute lymphocyte count (ALC), a readily available laboratory marker, can serve as a surrogate indicator of therapeutic response and long-term survival in patients receiving blinatumomab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A retrospective cohort study of adult patients with R\/R BCP-ALL treated with blinatumomab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed 162 adults with R\/R BCP-ALL who received up to two cycles of blinatumomab. The primary outcome was complete remission (CR), and secondary outcomes included overall survival (OS). ALC change from day 1 to day 14 (\u0394ALC14) was calculated, and its association with outcomes was assessed using logistic and Cox regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 162 patients, 106 (65.4%) achieved CR. \u0394ALC14 was significantly greater in responders than in non-responders (median 0.344 vs. 0.146 \u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). A high \u0394ALC14 (\u22650.100\u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L) was independently associated with higher response rates (OR: 2.96; P=0.004) and longer OS (median 15.3 vs. 7.0 months; P=0.007). Multivariate analysis confirmed high \u0394ALC14 as an independent predictor of response and favorable OS. Subgroup analyses suggested that the association between high \u0394ALC14 and response was more evident in first salvage than in later salvage (OR 8.40 vs. 1.82), whereas its association with OS was more evident in second or later salvage (median OS 14.5 vs. 4.3 months; P=0.005).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Early lymphocyte expansion during blinatumomab therapy, reflected by \u0394ALC14, is an independent predictor of treatment response. ALC monitoring may offer a simple, cost-effective tool for risk stratification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207261487003","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:47:36Z","timestamp":1788824856000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of early lymphocyte dynamics during blinatumomab therapy in relapsed or refractory B-cell precursor acute lymphoblastic leukemia: A real-world retrospective study"],"prefix":"10.1177","volume":"17","author":[{"given":"Seonghan","family":"Lee","sequence":"first","affiliation":[{"name":"The Catholic University of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daehun","family":"Kwag","sequence":"additional","affiliation":[{"name":"The Catholic University of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gi June","family":"Min","sequence":"additional","affiliation":[{"name":"The Catholic University of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[{"name":"The Catholic University of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Park","sequence":"additional","affiliation":[{"name":"The Catholic University of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9810-2050","authenticated-orcid":false,"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[{"name":"The Catholic University of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Sik","family":"Cho","sequence":"additional","affiliation":[{"name":"The Catholic University of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Seong","family":"Eom","sequence":"additional","affiliation":[{"name":"The Catholic University of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6653-2956","authenticated-orcid":false,"given":"Yoo-Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"The Catholic University of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[{"name":"The Catholic University of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[{"name":"The Catholic University of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[{"name":"The Catholic University of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-9131","authenticated-orcid":false,"given":"Jae-Ho","family":"Yoon","sequence":"additional","affiliation":[{"name":"The Catholic University of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20668"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.217"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004916"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404824"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.014274"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399287"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-018192"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-400515"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20908"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28136"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.6.2098"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402890"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.3531"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-798322"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-441030"},{"issue":"3","key":"e_1_3_8_20_2","first-page":"596","article-title":"Outcomes of children and young adults with B-cell acute lymphoblastic leukemia given blinatumomab as last consolidation treatment before allogeneic hematopoietic stem cell transplantation","volume":"110","author":"Algeri M","year":"2025","unstructured":"Algeri M, Massa M, Pagliara D, et al. Outcomes of children and young adults with B-cell acute lymphoblastic leukemia given blinatumomab as last consolidation treatment before allogeneic hematopoietic stem cell transplantation. Haematologica 2025; 110(3): 596\u2013607.","journal-title":"Haematologica"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312948"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.280078"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34667"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006287"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01089-x"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.41"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-649111"},{"key":"e_1_3_8_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-017-0074-5"},{"key":"e_1_3_8_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.0528"},{"key":"e_1_3_8_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw123"},{"key":"e_1_3_8_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01253-6"},{"key":"e_1_3_8_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.164"},{"key":"e_1_3_8_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31874"},{"key":"e_1_3_8_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-007-0298-z"},{"key":"e_1_3_8_35_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.804714"},{"key":"e_1_3_8_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2680"},{"key":"e_1_3_8_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231154713"},{"key":"e_1_3_8_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.12.009"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261487003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207261487003","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261487003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:20:40Z","timestamp":1789125640000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207261487003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"alternative-id":["10.1177\/20406207261487003"],"URL":"https:\/\/doi.org\/10.1177\/20406207261487003","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"article-number":"20406207261487003"}}